Table 2 Neonatal respiratory outcomes and related conditions between the dexamethasone and matched control groups

Respiratory distress, n (%)

8 (10.3)

18 (23.1)

0.38 (0.16–0.94); 0.036

0.29 (0.10–0.83);

0.021

Mild

5 (6.4)

7 (9.0)

0.70 (0.21–2.29);

0.53 (0.14–2.01); 0.349

Moderate

2 (2.6)

10 (12.8)

0.550

0.18 (0.35–0.98); 0.047

Severe

(1.3)

1 (1.3)

0.18 (0.04–0.85);

0.44 (0.03–7.86); 0.577

0.030

1.00 (0.06–16.28); 1.00

Respiratory support, n (%)

Supplemental oxygen

15 (19.2)

19 (24.4)

0.74 (0.34–1.59); 0.444

0.71 (0.31–1.66); 0.431

CPAP

2 (2.6)

5 (6.4)

0.38 (0.07–2.04); 0.262

0.22 (0.03–1.53); 0.127

Mechanical ventilation

1 (1.3)

1 (1.3)

1.00 (0.06–16.28);

0.44 (0.03–7.86);

1.00

0.577

Surfactant use, n (%)

1 (1.3)

1 (1.3)

1.00 (0.06–16.28); 1.00

0.44 (0.03–7.86);

0.577

Resuscitation at birth, n (%)

10 (12.8)

11 (14.1)

0.90 (0.36–2.25); 0.815

0.72 (0.26–2.05); 0.541

Apgar score, n (%)

 < 7 at 1 min

2 (2.6)

2 (2.6)

1.00 (00.14–7.28);

0.58 (0.07–5.12);

 < 7 at 5 min

1 (1.3)

0

1.00

0.620

-

-

Respiratory distress syndrome, n (%)

1 (1.3)

1 (1.3)

1.00 (0.06–16.28); 1.00

0.44 (0.03–7.86);

0.577

NICU admission, n (%)

24 (30.8)

32 (41.0)

0.64 (0.33–1.24);

0.183

0.57 (0.28–1.17);

0.570

Median length of hospital stay (IQR), days^b

5

(3.0 – 6.0)

5

(3.0 – 6.25)

1.01^b (0.88–1.16);

0.863

0.96^b (0.83–1.12); 0.600